Review article
https://doi.org/10.21857/y26kec3wo9
Colorectal cancer immunotherapy
Antonio Juretić
orcid.org/0000-0002-6379-9708
; Department of Clinical Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia; Oncology Clinic, University Hospital Centre Zagreb, Zagreb, Croatia
Abstract
Recent successful results of a relatively new immunotherapeutic anti-cancer strategy based on the blockade of immune inhibitory pathways by monoclonal antibodies against checkpoint molecules can be considered as a medical breakthrough in clinical cancer immunotherapy. This type of immunotherapy became a standard part of systemic therapy protocols in the treatment of some metastatic solid tumors such as melanoma, non-small cell lung cancer, genitourinary cancers, Merkel-cell carcinoma, squamous-cell carcinoma of the head and neck, and solid tumors with DNA high microsatellite instability or DNA mismatch-repair deficiency. Recent progress in colorectal cancer genome analysis, and also supported by clinical observations, indicates that patients with DNA mismatch repair deficiency or microsatellite instability-high metastatic colorectal cancers are a distinct biomarker-defined population that might benefit from immunotherapy treatment with monoclonal antibodies against checkpoint molecules. This treatment has therefore become a new treatment option for this colorectal cancer subgroup of patients. However, besides tumor microsatellite instability or mismatch-repair deficiency status, other predictive biomarkers are also needed since not all these tumors respond to anti-check point immunotherapy treatment. This paper aims to present a basic overview of immunotherapy in mismatch repair deficient colorectal cancer patients.
Keywords
colorectal cancer; biomarkers; immunotherapy; immunooncology; microsatellite instability; mismatch repair deficiency; personalized medicine
Hrčak ID:
201085
URI
Publication date:
13.6.2018.
Visits: 2.630 *